News

Eight years for nothing
Enlarge image

BusinessGermany

Eight years for nothing

17.10.2012 - The dreams of Wilex CEO Olaf Wilhelm to bring a drug to the market are destroyed. The company's most advanced compound has failed in Phase III.

On Tuesday evening, the Munich-based antibody developer reported results of a comprehensive Phase III study testing an anti-CA-IX antibody in the adjuvant treatment of renal cancer after surgery. The analysis showed no improvement in median disease free survival (approximately 72 months) following treatment with Rencarex compared with placebo. The Independent Data Monitoring Committee has recommended to terminate the Phase III ARISER trial which was started as long ago as in June 2004.

Originally, the company planned to announce the results in 2008. However, the number of adverse events did not come in as planned. Professor Seppo Pyrhoenen, Chairman of the ARISER IDMC, said: "I have over 30 years experience in treating patients with kidney cancer and applaud this study for being well balanced, controlled and very well conducted. This is probably the most comprehensive study in the adjuvant setting conducted in the past 20 years."

Wilex is also conducting Phase II trials with Mesupron in pancreatic and breast cancer and developing a diagnostic based on a radioactively labelled version of Rencarex in Phase III. At the Frankfurt stock exchange, Wilex shares fell more than 60%. The biggest shareholder is SAP founder Dietmar Hopp.

© eurobiotechnews.eu/pd

http://www.european-biotechnology-news.com/news/news/2012-04/eight-years-for-nothing.html

BusinessBelgiumSpain

31.07.2015 Spanish business developer Genetrix has sold its clinical stage cell therapy development subsidiary Coretherapix to Belgian TiGenix in a deal worth up to €267m.

BusinessUKSwitzerland

29.07.2015 Newly founded Mereo BioPharma has acquired three mid-stage clinical assets from Novartis. In turn, the Swiss pharma concern will hold a stake in the UK company. Other investors are also on board.

M&AIreland

28.07.2015 Irish Allergan is bolstering its product pipeline with a takeover of CNS specialist Naurex. At the same time, the company is divesting its global generics business to Teva.

Public marketGermanyFranceBelgiumFinlandDenmarkUK

24.07.2015 Biotech companies across Europe continue to raise cash on the public markets, generating €3bn in total financing proceedings in the first half of 2015. Compared to 2014, this is almost twice as much.

FinanceFrance

23.07.2015 US money keeps flowing into Europe's biotechs. As the race for the peanut allergy market heats up, NASDAQ listed French biotech DBV has announced the successful closing of US$281m (€256m) share offering for its allergy products.

BioplasticsFrance

21.07.2015 French biotech Deinove has launched a R&D programme to produce the versatile chemical intermediate muconic acid by using a designer variant of the Deinococcus bacteria.

BusinessFrance

16.07.2015 Sanofi has announced plans to restructure its business in five standalone global business units starting in January 2016. The goal is to promote growth and help the company launch a catalogue of new drugs over the next five years.

R&DUK

15.07.2015 GlaxoSmithKline (GSK) has become the first drugmaker to join the Francis Crick Institute. It is a consortium made up of six scientific and academic institutes to conduct research and drug development in the UK. The new institute is set to become a world-leading centre of biomedical research and innovation.

FundingUK

13.07.2015 UK drug developer ReNeuron has pulled in £68.4m (€96m) for its cell therapy pipeline for stroke and blindness treatments. Biotech guru Neil Woodford increases his fund’s stake in ReNeuron.

BusinessSweden

10.07.2015 Karolinska Development has slashed the reported value of its portfolio by almost half by revising its valuation model for early stage companies and divesting its shares in pain med maker Pharmanest.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTIE THERAPEUTICS (FI)0.23 EUR43.75%
  • DIAXONHIT (F)0.79 EUR14.49%
  • ACTIVE BIOTECH (S)12.35 SEK10.27%

FLOP

  • ZELTIA (E)3.69 EUR-8.44%
  • SWEDISH ORPHAN BIOVITRUM (S)13.05 USD-6.12%
  • ALMIRALL (E)17.75 EUR-5.84%

TOP

  • DBV TECHNOLOGIES (F)79.24 EUR50.2%
  • BIOTIE THERAPEUTICS (FI)0.23 EUR43.8%
  • DIAXONHIT (F)0.79 EUR43.6%

FLOP

  • BIOTEST (D)25.52 EUR-63.3%
  • BIOTECH PHARMACON (N)9.45 NOK-46.0%
  • EVOCUTIS (UK)0.17 GBP-22.7%

TOP

  • ADOCIA (F)86.78 EUR577.4%
  • FORMYCON (D)28.40 EUR323.2%
  • DBV TECHNOLOGIES (F)79.24 EUR317.5%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-88.9%
  • NEUROVIVE PHARMACEUTICAL AB (S)22.10 SEK-70.6%
  • NEOVACS (F)1.02 EUR-68.6%

No liability assumed, Date: 02.08.2015